Drug Profile
Gevokizumab - XOMA/Novartis
Alternative Names: S-78989; VPM 087; XMA-005.2; XMA-0052; XOMA-052Latest Information Update: 19 Feb 2024
Price :
$50
*
At a glance
- Originator XOMA
- Developer IRIS; National Eye Institute; North Shore-Long Island Jewish Health System; Novartis; Servier; University of Zurich; XOMA
- Class Antiacnes; Antineoplastics; Antirheumatics; Cardiovascular therapies; Eye disorder therapies; Immunotherapies; Vascular disorder therapies
- Mechanism of Action Interleukin 1 beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Uveitis
- Phase II Acne vulgaris; Acute coronary syndromes; Colorectal cancer; Diabetic nephropathies; Giant cell arteritis; Labyrinthitis; Myositis; Osteoarthritis; Schnitzler syndrome; Scleritis
- Phase I Gastric cancer; Oesophageal cancer; Renal cell carcinoma
- Suspended Rheumatoid arthritis
- No development reported Cancer; Gout; Juvenile rheumatoid arthritis; Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Discontinued Pyoderma
Most Recent Events
- 19 Feb 2024 Gevokizumab is still in phase I development in Colorectal cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in Czech Republic, Japan, Singapore and UK (IV) (NCT03798626)
- 19 Feb 2024 Gevokizumab is still in phase I development in Gastric-cancer(Combination therapy, Metastatic disease, Second-line therapy or greater) in Czech Republic, Japan, Singapore and UK (IV) (NCT03798626)
- 19 Feb 2024 Gevokizumab is still in phase I development in Oesophageal cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in Czech Republic, Japan, Singapore and UK (IV) (NCT03798626)